PAVmed Inc. announced that it expects to receive $11.11111 million in funding from Lucid Diagnostics Inc. and others

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.